COST-EFFECTIVENESS OF CRIZOTINIB FOR SECOND AND THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN ECUADOR

被引：0
|
作者：
Freire, V [1 ]
Cabezas, M. [2 ]
Salcedo, E. [2 ]
Albert, A. [3 ]
机构：
[1] Medikogeneticheskiy Nauchnyytsentr, Moscu, Russia
[2] Pontifical Catholic Univ, Quito, Ecuador
[3] Univ Liege, Liege, Belgium
来源：
VALUE IN HEALTH | 2018年 / 21卷
关键词：
D O I：
10.1016/j.jval.2018.04.194
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN117
引用
收藏
页码：S30 / S31
页数：2
相关论文
共 50 条
  • [1] COST-EFFECTIVENESS OF CRIZOTINIB FOR FIRST-LINE TREATMENT IN NON-SMALL CELL LUNG CANCER IN ECUADOR
    Salcedo, E.
    Freire, V
    Cabezas, M.
    Albert, A.
    [J]. VALUE IN HEALTH, 2018, 21 : S32 - S32
  • [2] COST-EFFECTIVENESS ANALYSIS OF ERLOTINIB VERSUS DOCETAXEL AS A SECOND- OR THIRD-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER IN KOREA
    Kim, Y. G.
    Lee, E. K.
    [J]. VALUE IN HEALTH, 2010, 13 (07) : A514 - A514
  • [3] COST-EFFECTIVENESS ANALYSIS OF ANLOTINIB AS A THIRD-LINE OR FURTHER TREATMENT IN ADVANCED NON-SMALL LUNG CANCER
    Huang, J.
    [J]. VALUE IN HEALTH, 2020, 23 : S48 - S48
  • [4] Cost-effectiveness analysis of anlotinib as a third-line or further treatment for advanced non-small cell lung cancer in China
    Zhu, Qiuyan
    Ni, Ronghua
    Guan, Xin
    [J]. TRANSLATIONAL LUNG CANCER RESEARCH, 2023, 12 (08) : 1782 - 1789
  • [5] Cost-effectiveness of nivolumab monotherapy in the third-line treatment of small cell lung cancer
    Smare, Caitlin
    Dave, Kiran
    Juarez-Garcia, Ariadna
    Abraham, Pranav
    Penrod, John R.
    Camidge, D. Ross
    Yuan, Yong
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1124 - 1133
  • [6] COST-EFFECTIVENESS OF THE SECOND LINE TREATMENT FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Chang, C. W.
    Lang, H. C.
    [J]. VALUE IN HEALTH, 2019, 22 : S165 - S166
  • [7] Cost-effectiveness analysis of tislelizumab, nivolumab and docetaxel as second- and third-line for advanced or metastatic non-small cell lung cancer in China
    Zhou, Dongchu
    Luo, Xia
    Zhou, Zhen
    Zeng, Xiaohui
    Wan, Xiaomin
    Tan, Chongqing
    Liu, Qiao
    [J]. FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [8] Second- and third-line treatments in non-small cell lung cancer
    Kumar A.
    Wakelee H.
    [J]. Current Treatment Options in Oncology, 2006, 7 (1) : 37 - 49
  • [9] COST-EFFECTIVENESS IN THE SECOND-LINE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC) IN THE US
    Graham, C.
    Knox, H.
    Hess, L. M.
    Jen, M.
    Carter, Cuyun G.
    Chandrawansa, K.
    Boye, M.
    [J]. VALUE IN HEALTH, 2015, 18 (07) : A457 - A458
  • [10] A cost-effectiveness analysis of docetaxel in the second-line treatment of non-small cell lung cancer
    Holmes, J
    Dunlop, D
    Hemmett, L
    Sharplin, P
    Bose, U
    [J]. PHARMACOECONOMICS, 2004, 22 (09) : 581 - 589
12345